OBGYN

Georgia School of Orthodontics Awards Atlanta Area Youths Complimentary Orthodontic Care

Retrieved on: 
Tuesday, March 5, 2024

Atlanta, Georgia--(Newsfile Corp. - March 5, 2024) - In keeping with Georgia School of Orthodontics' (GSO) overarching commitment and mission to give back to the Atlanta community, GSO has selected two Atlanta area children for complimentary orthodontic care through its annual Gift of a Smile program.

Key Points: 
  • Atlanta, Georgia--(Newsfile Corp. - March 5, 2024) - In keeping with Georgia School of Orthodontics' (GSO) overarching commitment and mission to give back to the Atlanta community, GSO has selected two Atlanta area children for complimentary orthodontic care through its annual Gift of a Smile program.
  • Georgia School of Orthodontics GSO) awarded two Atlanta students with free braces and complimentary orthodontic care through its Gift of a Smile program.
  • The three programs combined have provided more than $250,000 in complimentary orthodontic care to over 70 deserving children, adults and veterans in metro Atlanta.
  • "A critical part of Georgia School of Orthodontics' mission is to provide the highest quality orthodontic care at a lower cost than private practice orthodontics in the school's two patient clinics in Atlanta and Duluth.

Ovation Fertility Welcomes Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), as Cincinnati Lab Director

Retrieved on: 
Tuesday, February 20, 2024

Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.

Key Points: 
  • Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.
  • Dr. Warikoo comes to Ovation from the Bethesda Fertility Center Reproductive Study Lab in Cincinnati, where he has served as scientific director for more than 25 years.
  • “Ovation’s expansion in the Cincinnati area involves a close partnership with our partner physicians at the Institute for Reproductive Health, which combined with Bethesda Fertility Center effective February 1,” says Conor Beardsley, President of Ovation Fertility.
  • He is board certified by the American Board of Bioanalysis as a High Complexity Laboratory Director, Embryology Laboratory Director and Clinical Consultant.

Power to Decide Statement on Over-the-Counter Birth Control Release and Pricing

Retrieved on: 
Monday, March 4, 2024

WASHINGTON, March 4, 2024 /PRNewswire-PRWeb/ -- Today, the pharmaceutical company Perrigo announced that it will begin shipping the first ever FDA-approved over-the-counter (OTC) daily oral contraceptive pill, Opill, to retailers across the country. This marks a historic advancement in access to contraception, which for decades advocates have been fighting for.

Key Points: 
  • While the OTC birth control pill will greatly increase contraceptive access, the price will continue to be a barrier for many.
  • At Power to Decide, we will continue to push for everyone to have equitable access to take control of their reproductive and sexual health care."
  • Bedsider , a program of Power to Decide, is an evidence-based digital platform that offers medically-accurate, relevant, and resonate information on all aspects of reproductive well-being, including sex, sexual health, and birth control.
  • Find a birth control method that works for you at Bedsider.org.

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Retrieved on: 
Thursday, February 15, 2024

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
  • Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
  • “We’re thrilled to welcome Dallas to the Myriad team.
  • She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.

Montefiore Awarded $2 Million New York State Department of Health Grant to Advance the Education and Training of Community Health Workers

Retrieved on: 
Tuesday, January 9, 2024

BRONX, N.Y., Jan. 9, 2024 /PRNewswire/ -- There is growing recognition that community health workers (CHWs), local experts who fill gaps between medical care and social services, represent an enormous opportunity to address challenges in healthcare access and improve overall health outcomes. Despite their importance, inconsistencies in education and training prevent CHWs from reaching their full potential. The Community Health Worker Institute (CHWI) at Montefiore has received a $2 million grant from the New York State Department of Health to create a robust program that can serve as a new model for prospective and current CHW instruction and support.

Key Points: 
  • Despite their importance, inconsistencies in education and training prevent CHWs from reaching their full potential.
  • The Community Health Worker Institute (CHWI) at Montefiore has received a $2 million grant from the New York State Department of Health to create a robust program that can serve as a new model for prospective and current CHW instruction and support.
  • The CHWI at Montefiore launched in 2021, and to date, CHWs completed certificate training through Hostos Community College.
  • Most basic CHW training programs include approximately 81 hours of educational activities and 80 hours of on-the-job training.

Teal Health Partners with Leading Health Organizations in a Nationwide Clinical Trial for their Self-Collect Device for Cervical Cancer Screening, the Teal Wand™

Retrieved on: 
Tuesday, January 9, 2024

SAN FRANCISCO, Jan. 9, 2024 /PRNewswire/ -- Today, in honor of Cervical Cancer Awareness Month, Teal Health, a women's health company focused on increasing access to cervical cancer screenings in the US, announces the SELF-CERV clinical study, in progress at leading health organizations including Johns Hopkins, Yale University, University of Colorado, University of Wisconsin, Washington University, and many more. Teal Health's clinical trial is designed to support FDA submission and approval of their novel at-home self-collect device, the Teal Wand™. By offering an alternative to an in-person doctor's visit for a speculum exam, Teal Health will be able to provide women and people with a cervix a choice and greater access to this critical health screening, on which 1 in 4 women in the US are not up-to-date.

Key Points: 
  • Teal Health's clinical trial is designed to support FDA submission and approval of their novel at-home self-collect device, the Teal Wand™.
  • More than 50% of these diagnoses are later stage and among people who did not have a recent screening.
  • HPV testing is recommended as the preferred cervical cancer screening method by multiple medical guidelines, including the American Cancer Society.
  • This Cervical Cancer Awareness Month, Teal Health is raising awareness about the importance of life-saving cervical cancer screening with their 'Close the Screening Gap' initiative.

Tech Tips: Nine Ways Mercy Simplifies Health Care in 2024

Retrieved on: 
Friday, January 5, 2024

ST. LOUIS, Jan. 5, 2024 /PRNewswire/ -- In the midst of hectic schedules and endless to-do lists, managing health care just got easier, thanks to Mercy.

Key Points: 
  • ST. LOUIS, Jan. 5, 2024 /PRNewswire/ -- In the midst of hectic schedules and endless to-do lists, managing health care just got easier, thanks to Mercy.
  • Mercy's consumer experience and technology teams have created user-friendly platforms designed to make managing health care easier.
  • Mercy is constantly innovating and using the latest technology so consumers can more easily access care.
  • For nearly 200 years, the Sisters of Mercy have pursued health care access for all.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Retrieved on: 
Monday, November 13, 2023

“The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).

Key Points: 
  • “The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).
  • Sildenafil Cream is an investigational, proprietary topical cream formulation specifically designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women.
  • "These additional data from the Phase 2b RESPOND study, which demonstrated improvements in a broader population of women, underscore the meaningful potential for Sildenafil Cream in women's sexual health.
  • There is a critical unmet need for a safe, effective and ‘on demand' solution to difficulties with sexual arousal."

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?